Rivoglitazone
Rivoglitazone
Rivoglitazone (pronounced as ri-vo-gli-ta-zone) is a thiazolidinedione derivative, which is a class of antidiabetic drugs that are used in the management of type 2 diabetes.
Etymology
The term 'Rivoglitazone' is derived from the combination of the words 'Rivo' and 'glitazone'. 'Rivo' is a prefix used in pharmaceutical nomenclature, while 'glitazone' is a suffix used for drugs that belong to the thiazolidinedione class.
Pharmacology
Rivoglitazone works by binding to the peroxisome proliferator-activated receptor gamma (PPARγ), a type of nuclear receptor that is highly expressed in tissues that regulate glucose levels, such as adipose tissue and the liver. By activating PPARγ, Rivoglitazone increases the transcription of insulin-responsive genes, leading to better glucose control.
Related Terms
- Thiazolidinedione: A class of drugs that Rivoglitazone belongs to. These drugs are used to treat type 2 diabetes by reducing insulin resistance.
- Peroxisome proliferator-activated receptor gamma (PPARγ): A nuclear receptor that Rivoglitazone binds to in order to exert its antidiabetic effects.
- Type 2 diabetes: A chronic condition that Rivoglitazone is used to manage. It is characterized by high blood sugar levels due to insulin resistance or a lack of insulin.
See Also
External links
- Medical encyclopedia article on Rivoglitazone
- Wikipedia's article - Rivoglitazone
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski